A multicentre, observational cohort study to determine the efficacy and safety of lumacaftor/ivacaftor in patients with severe lung disease and cystic fibrosis
| Autor: | Koliarne Tong, Douglas Dorahy, Megan France, Lucy Burr, Hugh Greville, Simone Visser, Peter Middleton, Claire Wainwright, Daniel Barker, Peter Wark |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Exacerbation business.industry Lumacaftor Retrospective cohort study medicine.disease Cystic fibrosis Ivacaftor 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine 030228 respiratory system chemistry Internal medicine Cohort medicine In patient sense organs 030212 general & internal medicine business Cohort study medicine.drug |
| Zdroj: | Cystic fibrosis. |
| DOI: | 10.1183/13993003.congress-2019.oa2126 |
| Popis: | Background: Lumacaftor/ivacaftor (LUM/IVA) has been shown to improve percent predicted FEV1 (ppFEV1) and reduce exacerbation frequency in patients with ppFEV1 40 – 90. However, there is limited safety or efficacy data on its use in patients with ppFEV1 Aim: To determine the safety and efficacy of LUM/IVA in patients > 12 years of age with cystic fibrosis (CF), homozygous for F508del CFTR mutation and with ppFEV1 Methods: A retrospective cohort design was used. Data was collected from patients > 12 years of age with CF, homozygous for F508del CFTR mutation and with ppFEV1 Results: Data was collected from 132 patients; 72 patients on LUM/IVA and 60 matched controls. The rate of pulmonary exacerbations in patients on LUM/IVA was 40% lower than in the control group. Chest tightness or dyspnoea was experienced in 54% of patients on LUM/IVA, and treatment was discontinued in 43%. Conclusion: In this cohort of patients with CF and ppFEV1 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|